ZHX2 and cancer

doi:10.3760/cma.j.issn.1673-422X.2013.12.008

Abstract

Abstract: Transcription repressor ZHX2 is one of the members in ZHX protein family, which exists widely in human tissue and participates in the occurrence and development of various diseases. Researches show that ZHX2 is closely related to the occurrence and development of cancers, such as liver cancer, multiple myeloma, gastric cancer and colorectal cancer, which has the potential value of tumor treatment.

Key words: Zinc fingers, Homeodomain proteins, Neoplasms, Transcription factors

FU Shi-Jie, GUO Qing-He. ZHX2 and cancer[J]. Journal of International Oncology, 2013, 40(12): 905-907.

References

［1］ Kawata H, Yamada K, Shou Z, et al. Zincfingers and homeoboxes (ZHX) 2, a novel member of the ZHX family as a transcriptional repressor. Biochem J, 2003, 373 (Pt 3): 747757. ［2］ Shen H, Luan F, Liu H, et al. ZHX2 is a repressor of alphafetoprotein expression in human hepatoma cell lines. J Cell Mol Med, 2008, 12(68): 27722780. ［3］ Li MS, Li PF, He SP, et al. The promoting molecular mechanism of alphafetoprotein on the growth of human hepatoma Bel7402 cell line. World J Gastroenterol, 2002, 8(3): 469475. ［4］ Cavin LG, Venkatraman M, Factor VM, et al. Regulation of alphafetoprotein by nuclear factorkappaB protects hepatocytes from tumor necrosis factoralpha cytotoxicity during fetal liver development and hepatic oncogenesis. Cancer Res, 2004, 64 (19): 70307038. ［5］ Perincheri S, Dingle RW, Peterson ML, et al. Hereditary persistence of alphafetoprotein and H19 expression in liver of BALB/cJ mice is due to a retrovirus insertion in the Zhx2 gene. Proc Natl Acad Sci USA, 2005, 102(2): 396401. ［6］ Lv Z, Zhang M, Bi J, et al. Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular carcinoma. Am J Clin Pathol, 2006, 125(5): 740746. ［7］ Kittaka N, Takemasa I, Takeda Y, et al. Molecular mapping of human hepatocellular carcinoma provides deeper biological insight from genomic data. Eur J Cancer, 2008, 44(6): 885897. ［8］ Shirakawa H, Suzuki H, Shimomura M, et al. Glypican3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci, 2009, 100(8): 14031407. ［9］ Morford LA, Davis C, Jin L, et al. The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alphafetoprotein regulator 2. Hepatology, 2007, 46(5): 15411547. ［10］ Maurel M, Dejeans N, Taouji S, et al. MicroRNA1291mediated silencing of IRE1α enhances Glypican3 expression. RNA, 2013, 19(6): 778788. ［11］ Shih HC, Shiozawa T, Kato K, et al. Immunohistochemical expression of cyclins, cyclindependent kinases, tumorsuppressor gene products, Ki67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol, 2003, 34(5): 471478. ［12］ MüllerTidow C, Metzger R, Kügler K, et al. Cyclin E is the only cyclindependent kinase 2associated cyclin that predicts metastasis and survival in early stage nonsmall cell lung cancer. Cancer Res, 2001, 61(2): 647653. ［13］ Ohashi R, Gao C, Miyazaki M, et al. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res, 2001, 21(1B): 657662. ［14］ Yue X, Zhang Z, Liang X, et al. Zinc fingers and homeoboxes 2 inhibits hepatocellular carcinoma cell proliferation and represses expression of Cyclin A and E. Gastroenterology, 2012, 142(7): 15591570. ［15］ Gargalovic PS, Erbilgin A, Kohannim O, et al. Quantitative trait locus mapping and identification of Zhx2 as a novel regulator of plasma lipid metabolism. Circ Cardiovasc Genet, 2010, 3(1): 6067. ［16］ Watts GS, Oshiro MM, Junk DJ, et al. The acetyltransferase p300/CBPassociated factor is a p53 target gene in breast tumor cells. Neoplasia, 2004, 6(3): 187194. ［17］ Cui R, Nguyen TT, Taube JH, et al. Family members p53 and p73 act together in chromatin modification and direct repression of alphafetoprotein transcription. J Biol Chem, 2005, 280(47): 3915239160. ［18］ Lu ZL, Luo DZ, Wen JM. Expression and significance of tumorrelated genes in HCC. World J Gastroenterol, 2005, 11(25): 38503854. ［19］ Aoki T, Miyamoto A, Marubashi S, et al. Clinical value of alterations in p73 gene, related to p53 at 1p36, in human hepatocellular carcinoma. Int J Oncol, 2004, 24(2): 441446. ［20］ Legartova S, HarnicarovaHorakova A, Bartova E, et al. Expression of RAN, ZHX2, and CHC1L genes in multiple myeloma patients and in myeloma cell lines treated with HDAC and Dnmts inhibitors. Neoplasma, 2010, 57(5): 482487. ［21］ Armellini A, Sarasquete ME, GarcíaSanz R, et al. Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. Br J Haematol, 2008, 141(2): 212215. ［22］魏晶晶, 吕自力, 党裔武, 等. 结直肠癌中ZHX2蛋白表达的检测及其临床病理意义. 临床与实验病理学杂志, 2012, 28(2): 128131. ［23］ Hoffman WH, Biade S, Zilfou JT, et al. Transcriptional repression of the antiapoptotic surviving gene by wild type p53. J Biol Chem, 2002, 277(5): 32473257. ［24］ Morachis JM, Murawsky CM, Emerson BM. Regulation of the p53 transcription response by structurally diverse core promoters. Genes Dev, 2010, 24(2): 135147. ［25］陈其军, 吕自力, 党裔武, 等. 转录抑制因子ZHX2在胃癌组织中的表达及临床意义. 世界华人消化杂志, 2011, 19 (30): 31633167.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.

ZHX2 and cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments